

**Sunday, May 30 2021****CHANNEL 1****09:00 - 11:30      WS01 - Cervical Cancer Screening Organization Around the World****Co-chairs      Sandra VAN DIJK (NETHERLANDS), Francesca CAROZZI (ITALY)**

In this workshop, we'll hear and talk about the organization of screening programs around the world. Which organizations are involved? Who is responsible for decision making? How are women selected and invited? How is the program financed? How is monitoring and evaluation designed? We'll discuss best practices and challenges.

- Live introduction  
**Sandra VAN DIJK (NETHERLANDS)**
  - Organization of screening in Flanders (Belgium)  
**Eliane KELLEN (BELGIUM)**  
**Annemie HAELENS (BELGIUM)**
  - Organization of screening in the Netherlands  
**Sandra VAN DIJK (NETHERLANDS)**
  - Governance and organization of screening in the European Nordic countries  
**Veli-Matti PARTANEN (FINLAND)**
  - Organization of screening in Italy  
**Francesca CAROZZI (ITALY)**
  - Organization of screening in Canada  
**Erika NICHOLSON (CANADA)**
  - Organization of screening in Nepal  
**Sarita GHIMERE (NEPAL)**
  - Cervical cancer screening organization around the world - Live discussion
- 

**12:15 - 13:15      FC03 - Screening I****Chair      Francesca CAROZZI (ITALY)**

- Effects of opportunistic screening for cervical cancer in Germany: results from a population-based case-control study  
**Stefanie KLUG (GERMANY)**
  - Screening participation after a false positive screening result  
**Pernille Thordal LARSEN (DENMARK)**
  - HPV is looking around the corner, beware of the anus when you screen the cervix  
**Basile CACHE (SWITZERLAND)**
  - Lessons from HPV screening implementation within primary care in Burkina Faso  
**Keitly MENSAH (FRANCE)**
  - HPV screening: practical realization of WHO global strategy on cervical cancer elimination in Russia  
**Ilya OLKOV (RUSSIA)**
- 

**14:00 - 15:30      SS01 - First Void Urine as a Biomarker Source for Primary and Secondary HPV Related Cancer Prevention****Chair      Alex VORSTERS (BELGIUM)**

The use of self-sampling methods is becoming even more relevant in times where contacts and movement are being restricted. During this workshop we will discuss recent developments and achievements with first-void urine as biomarker source for primary and secondary cancer prevention

- Introduction: The rationale and potential of using urine samples in cervical cancer screening and HPV vaccination programs  
**Alex VORSTERS (BELGIUM)**
  - Comparison of initial stream urine with a vaginal self-sample for HPV testing in a referral population  
**Jack CUZICK (UNITED KINGDOM)**
  - EU-VALHUDES: VALidation of HUman papillomavirus assays and collection DEvices for HPV testing and preliminary results on urine samples  
**Clementina COCUZZA (ITALY)**
  - Test accuracy and acceptability of human papillomavirus in urine for detection of cervical neoplasia  
**Jennifer SMITH (USA)**
  - First-void urine as a biomarker source for triage of high-risk HPV positive women: where do we stand today  
**Severien VAN KEER (BELGIUM)**
  - HPV AB testing in First Void Urine Samples pre and post vaccination  
**Alex VORSTERS (BELGIUM)**
  - Live discussion  
**Clementina COCUZZA (ITALY)**  
**Jack CUZICK (UNITED KINGDOM)**  
**Jennifer SMITH (USA)**  
**Severien VAN KEER (BELGIUM)**  
**Alex VORSTERS (BELGIUM)**
-

**15:45 - 17:15 FC04 - HPV Vaccines I**

**Chair Silvia FRANCESCHI (ITALY)**

- Opening remarks from the Chair  
**Silvia FRANCESCHI (ITALY)**
  - HPV vaccine safety perceptions and adverse event reporting trends in the United States  
**Kalyani SONAWANE (USA)**
  - High coverage and adherence to dose intervals of the national school-based HPV vaccination program in Sweden 2012-2019  
**Jiangrong WANG (SWEDEN)**
  - HPV vaccination uptake in boys after introduction of gender-neutral HPV vaccination in Germany - a retrospective database analysis (IMS® vaccine analyzer)  
**Cornelia WÄHNER (GERMANY)**
  - Temporal trends in HPV vaccination during covid conditions in a Texas safety-net healthcare system  
**Susan PARKER (USA)**
  - Impact of vaccination strategy on the resilience of HPV16 herd effect in unvaccinated females following an abrupt halt in vaccination: age-period-cohort analysis following a community randomised trial  
**Penelope GRAY (FINLAND)**
  - Effect of the 9-valent human papillomavirus (9VHPV) vaccine in a subgroup of female clinical trial participants who underwent cervical surgery  
**Elmar JOURA (AUSTRIA)**
  - Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 1.1 million women in Norway  
**Ståle NYGÅRD (NORWAY)**
  - Immunogenicity of 1, 2, and 3 doses of 9-valent human papillomavirus (9VHPV) vaccine in girls 9–14 years of age  
**Alain LUXEMBOURG (USA)**
  - Immunogenicity of the nine-valent HPV vaccine in people living with HIV and solid organ transplant recipients  
**Lise BOEY (BELGIUM)**
  - Design of a phase 3 immunogenicity and safety study evaluating 2-dose regimens of 9-valent human papillomavirus (9VHPV) vaccine with extended dosing intervals  
**Rachael BONAWITZ (USA)**
  - Design of a phase 3 efficacy, immunogenicity, and safety study of 9-valent human papillomavirus (9VHPV) vaccine in prevention of oral persistent infection in men  
**Yingmei TU (USA)**
- 

**17:30 - 19:00 SS02 - HPV Vaccines Special Session**

**Chair Suzanne GARLAND (AUSTRALIA)**

- Introduction - Emerging data from the post-licensure program for the 9-valent (9VHPV) and quadrivalent (QHPV) human papillomavirus vaccines  
**Suzanne GARLAND (AUSTRALIA)**
  - HPV vaccination coverage rates in 53 WHO European countries  
**Paolo BONANNI (ITALY)**
  - Long-term follow-up (LTFU) studies evaluating effectiveness and immunogenicity of the quadrivalent (QHPV) and 9-valent (9VHPV) HPV vaccines in female clinical trial participants  
**Alfred J. SAAH (USA)**
  - Long-term effectiveness of quadrivalent (QHPV) and 9-valent (9VHPV) HPV vaccine in male clinical trial participants  
**Joel PALEFSKY (USA)**
  - Data systems utilized to assess the impact of HPV vaccination in high-income countries: a scoping review  
**Smita KOTHARI (USA)**
  - Real-world impact and effectiveness of the quadrivalent HPV vaccine: study designs and data sources  
**Wei-Vivian WANG (USA)**
  - Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review  
**Suzanne GARLAND (AUSTRALIA)**
  - Safety of 4-valent human papillomavirus vaccine among males in the United States  
**John SEEGER (USA)**
  - 9-valent human papillomavirus vaccine safe in routine use: observational study in more than 140,000 individuals  
**John HANSEN (USA)**
  - Post-marketing safety experience with the 9-valent human papillomavirus vaccine through December 2019  
**Veronica URDANETA (USA)**
-

**Sunday, May 30 2021****CHANNEL 2****09:00 - 10:30 FC01 - Management I****Chair Frederique VINK (NETHERLANDS)**

- Classification of high-grade CIN by P16, KI-67, HPV E4 and FAM19A4/MIR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management  
**Frederique VINK (NETHERLANDS)**
  - Risk of CIN3+ in HPV-positive women with normal cytology and five-year type concordance: a randomized comparison  
**Federica INTURRISI (NETHERLANDS)**
  - Optimal performance specifications for triage testing of primary HPV-positive specimens  
**Jeff ANDREWS (USA)**
  - Management of HPV-positive women in cervical cancer screening: risk stratification by HPV genotype and cytology  
**Louise T. THOMSEN (DENMARK)**
  - Clinical challenges in managing cervical intraepithelial neoplasia 2: report from a cross-sectional survey  
**Melissa BRADBURY (SPAIN)**
  - Are women after surgical treatment of high grade cervical intraepithelial lesions followed-up according to guidelines?  
**Nina JANCAR (SLOVENIA)**
  - Efficacy of PAPILOCARE in HPV-positive women aged over 40 years: subanalysis of the PAPILOBS study  
**Damian DEXEUS (SPAIN)**
- 

**10:45 - 11:50 FC02 - HPV Testing / Molecular Markers I****Chair Hans IKENBERG (GERMANY)**

- Circulating HPV DNA in cervical cancer: a marker for early detection of relapse  
**Emmanuelle JEANNOT (FRANCE)**
  - Multiplexed quantification of biomarkers detects dysplasia with high accuracy: a validation of the QG-MPH using RT-QPCR  
**Anna Sophie SKOF (GERMANY)**
  - Evaluation of DYSKERIN expression and the CAJAL body protein WRAP53? as potential prognostic markers for patients with primary vaginal carcinoma  
**Cecilia RANHEM (SWEDEN)**
  - Quantigene-molecular profiling histology assay detects dysplasia from primary cervical smear samples with high precision by multiplexed mRNA quantitation of biomarkers  
**Andreas Martin KAUFMANN (GERMANY)**
  - Circulating HPV DNA as a biomarker in patients with HPV related cervical carcinoma  
**Stacey BRYAN (UNITED KINGDOM)**
- 

**14:00 - 15:30 WS02 - Vulvovaginal and Anal Diseases- Part I****Co-chairs Gilbert DONDERS (BELGIUM), Jorma PAAVONEN (FINLAND)**

- Live introduction  
**Gilbert DONDERS (BELGIUM)**  
**Jorma PAAVONEN (FINLAND)**
  - Vulvar dermatoses: natural history and risk for malignancy  
**Angelika STARY (AUSTRIA)**
  - Bacterial vaginosis and dysbiosis  
**Gilbert DONDERS (BELGIUM)**
  - Aerobic vaginitis  
**Jorma PAAVONEN (FINLAND)**
  - Vulvodynia: Pitfalls in the diagnosis  
**Gilbert DONDERS (BELGIUM)**
  - Selected case presentations  
**Gilbert DONDERS (BELGIUM)**
  - Live discussion  
**Gilbert DONDERS (BELGIUM)**  
**Jorma PAAVONEN (FINLAND)**  
**Angelika STARY (AUSTRIA)**
-

**15:45 - 18:00**      **WS02 - Vulvovaginal and Anal Diseases - Part II**

**Chair**                      **Jacob BORNSTEIN (ISRAEL)**

INTERACTIVE COURSE

- Introduction  
**Jacob BORNSTEIN (ISRAEL)**
- Lichen sclerosus resistant to therapy  
**Mario PRETI (ITALY)**
- Vaginal microbiome and HPV  
**Pedro VIEIRA-BAPTISTA (PORTUGAL)**
- Break
- Anal intraepithelial neoplasia  
**Joel PALEFSKY (USA)**
- Social media and the vulvar disease expert  
**Mario PRETI (ITALY)**
- Live discussion  
**Jacob BORNSTEIN (ISRAEL)**  
**Joel PALEFSKY (USA)**  
**Mario PRETI (ITALY)**  
**Pedro VIEIRA-BAPTISTA (PORTUGAL)**

---

**Sunday, May 30 2021**

**CHANNEL 3**

**09:00 - 10:30**      **HN01 - Epidemiology and Screening**

**Co-chairs**                      **Tim WATERBOER (GERMANY), Ulrike WIELAND (GERMANY)**

- Live introduction  
**Tim WATERBOER (GERMANY)**  
**Ulrike WIELAND (GERMANY)**
- Biomarkers for HPV-OPC  
**Elena-Sophie PRIGGE (GERMANY)**
- Familial occurrence of OPSCC and other HPV-associated cancers  
**Kari HEMMINKI (GERMANY)**
- Screening for HPV-OPC: Overview of screening concepts  
**Hilary ROBBINS (FRANCE)**
- Risk-stratified screening of OPSCC - Proof of concept trial  
**Matti LEHTINEN (SWEDEN)**
- Cost-effectiveness of OPSCC elimination  
**Simopekka VÄNSKÄ (FINLAND)**
- Live discussion  
**Kari HEMMINKI (GERMANY)**  
**Elena-Sophie PRIGGE (GERMANY)**  
**Hilary ROBBINS (FRANCE)**  
**Simopekka VÄNSKÄ (FINLAND)**  
**Ulrike WIELAND (GERMANY)**

---

**10:45 - 12:15**      **HN02 - Management and Surveillance**

**Co-chairs**                      **Paolo BOSSI (ITALY), Amanda PSYRRI (GREECE)**

- Live introduction  
**Paolo BOSSI (ITALY)**  
**Amanda PSYRRI (GREECE)**
- Biomarker-based surveillance in HPV-associated OSCC  
**Martina BROGLIE DÄPPEN (SWITZERLAND)**
- Work up of unknown primary  
**Asit ARORA (UNITED KINGDOM)**
- Updates in deintensification  
**Chia-Jung BUSCH (GERMANY)**
- Impact of deintensification on HRQOL outcomes  
**Christian SIMON (SWITZERLAND)**
- Surgical deintensification  
**Terry JONES (UNITED KINGDOM)**
- Live discussion  
**Paolo BOSSI (ITALY)**  
**Martina BROGLIE DÄPPEN (SWITZERLAND)**  
**Terry JONES (UNITED KINGDOM)**  
**Amanda PSYRRI (GREECE)**  
**Christian SIMON (SWITZERLAND)**

**12:30 - 13:30      HN03 - Submitted Papers I**

**Chair                    Jens Peter KLUSSMANN (GERMANY)**

- Live introduction  
**Jens Peter KLUSSMANN (GERMANY)**
  - Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 – Risk of incorrect downstaging of HPV-mediated non-tonsillar, non-base of tongue carcinomas  
**Anders NÅSMAN (SWEDEN)**
  - Patient derived ex vivo slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive OPSCC  
**Henrike Barbara ZECH (GERMANY)**
  - Epidemiologic and survival distinctions between base of tongue and tonsil oropharyngeal carcinomas  
**Melina WINDON (USA)**
  - Live discussion  
**Jens Peter KLUSSMANN (GERMANY)**  
**Anders NÅSMAN (SWEDEN)**  
**Melina WINDON (USA)**  
**Henrike Barbara ZECH (GERMANY)**
- 

**14:00 - 15:30      HN04 - Molecular and Immunologic Considerations**

**Co-chairs             Jan KLOZAR (CZECH REPUBLIC), Ernst-Jan SPEEL (NETHERLANDS)**

- Live introduction  
**Ernst-Jan SPEEL (NETHERLANDS)**
  - HPV viral integration  
**Shama VIRANI (FRANCE)**
  - Molecular modifiers of prognosis in HPV-OPC  
**Lisa LICITRA (ITALY)**
  - Role of biomarkers in HPV-OPC treatment  
**Nora WUERDEMANN (GERMANY)**
  - Targeted therapy for HPV-OPC - an option for the future?  
**Tina DALIANIS (SWEDEN)**
  - HPV-specific T cell response  
**Sjoerd H. VAN DER BURG (NETHERLANDS)**
  - Enhancing immune response to HPV-OPC with cell-based tumor vaccines  
**Oliver ROSEN (USA)**
  - Live discussion  
**Tina DALIANIS (SWEDEN)**  
**Jan KLOZAR (CZECH REPUBLIC)**  
**Lisa LICITRA (ITALY)**  
**Oliver ROSEN (USA)**  
**Ernst-Jan SPEEL (NETHERLANDS)**  
**Sjoerd H. VAN DER BURG (NETHERLANDS)**  
**Shama VIRANI (FRANCE)**
- 

**15:45 - 17:15      HN05 - Submitted Papers II**

**Chair                    Hisham M. MEHANNA (UNITED KINGDOM)**

- Live introduction  
**Hisham M. MEHANNA (UNITED KINGDOM)**
- ZNF671 – a promising epigenetic biomarker for improved detection of head and neck cancer in non-invasive specimen  
**Anna-Bawany HUMS (GERMANY)**
- A deficiency in the ATM-mediated DNA damage response contributes to the DNA repair defect of HPV-positive head and neck cancer  
**Thorsten RIECKMANN (GERMANY)**
- Quantigene-molecular profiling histology assay: HPV oncogene and biomarker mRNA detection and quantification for HNSCC samples  
**Sarah THIES (GERMANY)**
- Radiation-induced upregulation of DNA sensing pathways is dependent on HPV status of pharyngeal squamous cell carcinoma  
**Kristina LEVPUSCEK (SLOVENIA)**
- Anatomic classification of head and neck cancers based on ICD codes in the context of a global cross-sectional study to assess the fraction of head and neck cancers attributable to human papillomavirus (the broaden study)  
**Haïtham MIRGHANI (FRANCE)**
- Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma  
**Chamindie PUNYADEERA (AUSTRALIA)**
- The role of transoral robotic surgery in head and neck carcinoma of unknown primary - a single centre experience  
**Elsa LEE (UNITED KINGDOM)**  
**Nikoleta SKALIDI (UNITED KINGDOM)**
- Targeted therapy with FGFR and PI3K inhibitors on HPV positive and negative tonsillar and base of tongue cancer lines with and without corresponding mutations  
**Stefan HOLZHAUSER (SWEDEN)**

- Live discussion  
**Stefan HOLZHAUSER (SWEDEN)**  
**Anna-Bawany HUMS (GERMANY)**  
**Elsa LEE (UNITED KINGDOM)**  
**Kristina LEVPUSCEK (SLOVENIA)**  
**Haïtham MIRGHANI (FRANCE)**  
**Chamindie PUNYADEERA (AUSTRALIA)**  
**Thorsten RIECKMANN (GERMANY)**  
**Nikoleta SKALIDI (UNITED KINGDOM)**  
**Sarah THIES (GERMANY)**

## Monday, May 31 2021

## CHANNEL 1

**09:00 - 10:30**      **MSS01 - Novel Strategies in Risk-Based Cervical Cancer Screening**

**Co-chairs**      **Johannes BERKHOF (NETHERLANDS), Jack CUZICK (UNITED KINGDOM)**

The implementation of HPV-based screening and the opportunity of HPV testing on self-collected samples offers a wide range of options for risk stratification in cervical cancer screening. Risk-based screening is expected to provide a better balance of the benefits and harms of screening than a one-size-fits-all strategy since the natural history of cervical cancer and important risk factors are well-documented. In this session, experts in the field will share their latest insights on risk-based screening including views on self-sampling, the use of molecular markers, and screening during and after the Covid19 pandemic.

- Live introduction  
**Johannes BERKHOF (NETHERLANDS)**  
**Jack CUZICK (UNITED KINGDOM)**
- Stratification markers in self-sampling  
**Jack CUZICK (UNITED KINGDOM)**
- Novel strategies in risk-based cervical cancer screening  
**Talia MALAGON (CANADA)**
- Indication for methylation in screening and diagnosis  
**Chris MEIJER (NETHERLANDS)**
- Risk based screening in Europe: the RISCC consortium  
**Johannes BERKHOF (NETHERLANDS)**
- Restarting screening programs after the Covid-19 crisis: prioritization of risk groups  
**Miriam ELFSTRÖM (SWEDEN)**
- Cervical cancer screening during and after a global pandemic: strategies for returning to elective clinical encounters  
**Nicolas WENTZENSEN (USA)**
- Live discussion  
**Johannes BERKHOF (NETHERLANDS)**  
**Paolo BONANNI (ITALY)**  
**Jack CUZICK (UNITED KINGDOM)**  
**Miriam ELFSTRÖM (SWEDEN)**  
**Talia MALAGON (CANADA)**  
**Chris MEIJER (NETHERLANDS)**  
**Nicolas WENTZENSEN (USA)**

**10:45 - 12:00**      **MSS02 - Comparing Immune Responses Induced by Different HPV Vaccines and HPV Vaccine Doses**

**Chair, Co-chair**      **Michael PAWLITA (GERMANY), Matti LEHTINEN (SWEDEN)**

- Live introduction  
**Matti LEHTINEN (SWEDEN)**
- Cross-reactivity / sustainability of neutralizing antibodies after bi-/ quadrivalent vaccination  
**Filipe MARIZ (GERMANY)**
- Head-to-head comparison of bi- and nonvalent vaccine induces antibody responses  
**Carina EKLUND (SWEDEN)**
- Sustainability of neutralizing HPV antibodies following administration of 1-3 vaccine doses  
**Partha BASU (FRANCE)**
- Comparison of bi- and quadrivalent vaccine efficacies vs. neutralizing antibody levels  
**Matti LEHTINEN (SWEDEN)**
- Sensitivity of neutralizing HPV antibody response to between/ within type variation  
**Simon BEDDOWS (UNITED KINGDOM)**
- Definition of vaccine-induced protective antibody levels  
**Joakim DILLNER (SWEDEN)**
- Live discussion  
**Partha BASU (FRANCE)**  
**Simon BEDDOWS (UNITED KINGDOM)**  
**Joakim DILLNER (SWEDEN)**  
**Carina EKLUND (SWEDEN)**  
**Matti LEHTINEN (SWEDEN)**  
**Filipe MARIZ (GERMANY)**

**14:45 - 16:15 SS03 - Genomics, Biomarkers and Microbiome Using Metabolomics and Proteomics****Chair Anna-Barbara MOSCICKI (USA)**

Evidence strongly supports the role of the microbiome in influencing the progression of HPV to cervical precancers and cancers. However, some believe it's not just "bad" microbiome rather an interplay between genetic predisposition and response to the altered microbiome. The study of the microbiome and host and bacterial metabolites can give important insight into pathogenesis. In addition, microbiome or metabolome signatures preceding HPV clearance or progression to HSIL may be useful as biomarkers to identify women in need of more intense observation or treatment. Metabolomics has been successfully used for biomarker discovery and technologies are being developed for point-of-care testing using non-invasive fluids (e.g., urine, feces) in resource-poor setting. This session will review the interplay of genetics, microbiomes and metabolomics.

- Live introduction  
**Anna-Barbara MOSCICKI (USA)**
  - Host cell DNA methylation markers for cervical cancer  
**Danielle HEIDEMAN (NETHERLANDS)**
  - Vaginal dysbiosis and HPV  
**Nele BRUSSELAERS (SWEDEN)**
  - Interaction between HPV and microbiota using immune and metabolic profiling  
**Melissa HERBST-KRALOVETZ (GERMANY)**
  - Microbiological landscape of cervical cancer: microbial species, HPV transcriptomics and host-cell interactions  
**Karolina ANDRALOJC (NETHERLANDS)**
  - Live discussion  
**Karolina ANDRALOJC (NETHERLANDS)**  
**Nele BRUSSELAERS (SWEDEN)**  
**Danielle HEIDEMAN (NETHERLANDS)**  
**Melissa HERBST-KRALOVETZ (GERMANY)**  
**Anna-Barbara MOSCICKI (USA)**
- 

**16:30 - 18:00 MSS04 - Clinical Use and Validation of HPV Testing in Various Situations****Co-chairs Thomas IFTNER (GERMANY), Kate CUSCHIERI (UNITED KINGDOM)**

The increased use of HPV testing for screening and disease management, behoves the scientific community to consider optimal systems for the validation and refinement of HPV detection technologies. Furthermore, given the different populations/contexts in which HPV testing is appropriate; which differ with respect to their dimensions, accessibility and risk - specific demands on the tests should reflect these differences. To address this, in the session "Clinical use and validation of HPV testing in various situations – we will hear considerations on the validation of HPV tests when applied in varied contexts including as a self sampling option, for the triage of screen HPV positive women, as a triage of low grade disease and for the monitoring of women post-treatment. In addition the challenges of HPV test validation and application in vaccinated women and for disease beyond the cervix will be covered.

- Live introduction  
**Kate CUSCHIERI (UNITED KINGDOM)**  
**Thomas IFTNER (GERMANY)**
  - For triage of HPV+ women  
**Clementina COCUZZA (ITALY)**
  - For vaginal self sampling  
**Marc ARBYN (BELGIUM)**
  - For post-treatment follow-up  
**Nicolas WENTZENSEN (USA)**
  - For vaccinated women  
**Joakim DILLNER (SWEDEN)**
  - For risk stratification of non-cervical cancers  
**Kate CUSCHIERI (UNITED KINGDOM)**
  - Live discussion  
**Marc ARBYN (BELGIUM)**  
**Clementina COCUZZA (ITALY)**  
**Kate CUSCHIERI (UNITED KINGDOM)**  
**Joakim DILLNER (SWEDEN)**  
**Thomas IFTNER (GERMANY)**
-



**Monday, May 31 2021****CHANNEL 2****09:00 - 10:30 CS01 - Challenging Clinical Topics****Co-chairs Maria KYRGIU (UNITED KINGDOM), Andreas Martin KAUFMANN (GERMANY)**

- Live introduction  
**Maria KYRGIU (UNITED KINGDOM)**
  - Counseling patients in a world where an irritation of the cervix changes into a newly discovered STI  
**Gilbert DONDEERS (BELGIUM)**
  - Women with CIN2 lesions: is it a true precancerous lesion?  
**Ilkka KALLIALA (FINLAND)**
  - Involved margins – risk of cancer after excision: when is it safe not to treat?  
**Evangelos PARASKEVAIDIS (GREECE)**
  - Should we vaccinate women at the time of conization?  
**Maria KYRGIU (UNITED KINGDOM)**
  - Management dilemma of CIN 2-3 in pregnancy  
**Efraim SIEGLER (ISRAEL)**
  - Live discussion  
**Gilbert DONDEERS (BELGIUM)**  
**Ilkka KALLIALA (FINLAND)**  
**Maria KYRGIU (UNITED KINGDOM)**  
**Evangelos PARASKEVAIDIS (GREECE)**  
**Efraim SIEGLER (ISRAEL)**
- 

**10:45 - 12:15 CS02 - New Developments in Colposcopy Practice****Chair Achim SCHNEIDER (GERMANY)**

What service can or should be offered in a colposcopy clinic? This session is addressed to medical staff who perform a colposcopy clinic and also to medical personnel who refer patients to a colposcopy clinic. We define a spectrum of services which should be offered by a colposcopy clinic in addition to what is recommended by international performance standards: The quality of life of the patient has highest priority: no fear, no pain. Examination of the complete lower genital tract and discussion of all inconclusive findings in an interdisciplinary conference should be obligatory. Patients with complex or extensive disease need continuous support and guidance. The cause of vaginal bleeding also in absence of cervical disease must be investigated. Medical as well as hermeneutic quality criteria should be transparent and accessible for the public.

- Live introduction  
**Achim SCHNEIDER (GERMANY)**
  - What service can or should be offered in a colposcopy clinic?  
**Achim SCHNEIDER (GERMANY)**
  - Improving colposcopy practice: the tools  
**Evangelos PARASKEVAIDIS (GREECE)**
  - Are there situations where colposcopy is not mandatory before treatment?  
**Nicolas WENTZENSEN (USA)**
  - Implementing quality of assurance in colposcopy clinics in the era of HPV vaccination and HPV screening  
**Ameli TROPÉ (NORWAY)**
  - Live discussion  
**Evangelos PARASKEVAIDIS (GREECE)**  
**Achim SCHNEIDER (GERMANY)**  
**Ameli TROPÉ (NORWAY)**  
**Nicolas WENTZENSEN (USA)**
- 

**15:00 - 16:15 MSS03 - Cervical Cancer: Vaccine Impact and Vaccine Safety****Co-chairs Paolo BONANNI (ITALY), Joakim DILLNER (SWEDEN)**

The session "Cervical Cancer: Vaccine Impact and Vaccine Safety" will feature 5 of the most distinguished speakers in the field who will present the latest developments about how HPV vaccination strategies will impact the global cancer burden, the results on large-scale safety and real-life cancer impact that are already seen and the evidence on innovative vaccination and dosing strategies that are emerging.

- Live introduction  
**Paolo BONANNI (ITALY)**  
**Joakim DILLNER (SWEDEN)**
- HPV vaccination: global perspective and cervical cancer elimination goals  
**Matti LEHTINEN (SWEDEN)**
- Impact of HPV vaccination  
**Pär SPARÉN (SWEDEN)**
- Real life evaluation of safety and impact  
**Julia BROTHERTON (AUSTRALIA)**
- Single-dose HPV vaccination  
**Aimée KREIMER (USA)**
- Modelling the impact of HPV vaccination for cervical cancer elimination  
**Mark JIT (UNITED KINGDOM)**



- Live discussion  
**Paolo BONANNI (ITALY)**  
**Julia BROTHERTON (AUSTRALIA)**  
**Joakim DILLNER (SWEDEN)**  
**Mark JIT (UNITED KINGDOM)**  
**Aimée KREIMER (USA)**  
**Matti LEHTINEN (SWEDEN)**  
**Pär SPARÉN (SWEDEN)**

**16:30 - 18:00**      **SS04 - Male HPV: From Infection to Disease Control**

**Chair**                      **Eduardo FRANCO (CANADA)**

Understanding sexual transmission of HPV infection is essential in informing preventive practices, such as barrier methods, vaccination, and microbicidal gel use. This session will focus on the epidemiology and clinical characteristics of HPV infection and associated diseases in men, as well as on promising preventive strategies.

- Live introduction  
**Eduardo FRANCO (CANADA)**
- Epidemiology  
**Eduardo FRANCO (CANADA)**
- Transmission  
**Eduardo FRANCO (CANADA)**
- Anus  
**Joel PALEFSKY (USA)**
- Genitalia  
**Kathleen D'HAUWERS (NETHERLANDS)**
- Oropharyngeal cancer  
**Eleni RETTIG (USA)**
- Live discussion  
**Kathleen D'HAUWERS (NETHERLANDS)**  
**Eduardo FRANCO (CANADA)**  
**Joel PALEFSKY (USA)**  
**Eleni RETTIG (USA)**

**Monday, May 31 2021**

**CHANNEL 3**

**09:00 - 10:30**      **FC05 - Epidemiology**

**Chair**                      **Jennifer SMITH (USA)**

- Prevalence of human papillomavirus among females older than recommended age for vaccination by birth cohort, national health and nutrition examination survey, United States, 2003-2016  
**Julia GARGANO (USA)**
- Evolution of cervical high grade dysplasia during pregnancy and post partum: what role does the delivery route play?  
**Martine JACOT-GUILLARMOD (SWITZERLAND)**
- Prevalence of human papillomavirus among females older than recommended age for vaccination by number of lifetime partners, national health and nutrition examination survey, 2003-2016  
**Rayleen LEWIS (USA)**
- Age-specific prevalence of human papillomavirus and abnormal cytology in a diverse statewide cohort of individuals undergoing cervical cancer screening in Mississippi  
**Megan CLARKE (USA)**
- HPV73 in cervical cancer and distribution of HPV73 variants in cervical dysplasia  
**Ola FORSLUND (SWEDEN)**
- Risk factors for HPV infection & disease in adults: a literature summary  
**Marta DEL PINO (SPAIN)**
- Clearance of HPV after conization of cervical cancer and adenocarcinoma in situ correlates with absence of cancer  
**Efraim SIEGLER (ISRAEL)**
- Prevalence of genital HPV-infections among female transplant recipients  
**Linn WOELBER (GERMANY)**
- Cytology and HPV molecular epidemiology for 2,362 women engaged in cervical cancer screening in French university hospitals from 2016 to 2020  
**Valentine FERRE (FRANCE)**
- Treated and untreated human papillomavirus infection is associated with preterm delivery and neonatal mortality - a Swedish population-based study  
**Johanna WIIK (SWEDEN)**

**10:45 - 12:00 FC06 - Screening II**

**Chair Guglielmo RONCO (ITALY)**

- Investigating loss to follow-up in the Dutch cervical cancer screening programme  
**Ellen Maria Gezina OLT Hof (NETHERLANDS)**
  - HPV testing in Polish population-based cervical cancer screening program - interim analysis of a randomised health services study  
**Andrzej NOWAKOWSKI (POLAND)**
  - Predictions in the results of the second HRHPV screening round given the changing landscape: a modelling study  
**Sylvia KALJOUW (NETHERLANDS)**
  - HPV based screening strategy in younger women: a randomized controlled trial  
**Paola ARMAROLI (ITALY)**
  - Introduction of p16/Ki67 dual stain cytology in a Danish routine screening laboratory - Importance of adequate training and experience  
**Line W GUSTAFSON (DENMARK)**
  - The possible role of cytology and HR-HPV partial genotyping at 12-month recall in cervical cancer screening with HR-HPV primary test  
**Giampaolo POMPEO (ITALY)**
  - Registry-based assessment of diagnostic accuracy in cervical cancer screening in the Nordic countries  
**Veli-Matti PARTANEN (FINLAND)**
  - Experiences of the first year of routine co-testing cytology and HPV in Germany  
**Hans IKENBERG (GERMANY)**
  - Screening and vaccination: Results from an Italian study evaluating best strategies on how to screen vaccinated women  
**Francesca CAROZZI (ITALY)**
  - Outcome of first cervical screening round after spontaneous vaccination against HPV: an Italian cohort study  
**Silvia GORI (ITALY)**
- 

**14:45 - 15:55 FC07 - Self-Sampling**

**Chair Gilbert DONDEERS (BELGIUM)**

- Urine HPV-DNA detection for cervical cancer screening – analytical comparison of two HPV assays  
**Mette TRANBERG (DENMARK)**
  - Detection of HPV-specific antibodies in first-void urine of women vaccinated with a nonavalent HPV vaccine  
**Laura TÉBLICK (BELGIUM)**
  - Workflow and performance of CE marked BD Onclarity assay with self-collection on the BD Viper LT System  
**Laurence VAUGHAN (USA)**
  - Cocoss-trial: concurrent comparison of self-sampling devices for HPV-detection  
**Matthias JENTSCHKE (GERMANY)**
  - Performance of 6 methylation markers tested on self-collected urine samples - feasibility study  
**Martina SCHMITZ (GERMANY)**
  - Preferences and experiences regarding the use of the self-sampling device in the hrHPV screening for cervical cancer  
**Jolien DE WAARD (NETHERLANDS)**
- 

**16:30 - 17:45 FC08 - Methylation**

- Preventing overtreatment of CIN2/3 lesions: the role of methylation markers in predicting (non-)regression. Results of the CONSERVE study.  
**Stéfanie DICK (NETHERLANDS)**
  - Methylation analysis as a tool in cervical cancer screening  
**Ylva LINDROTH (SWEDEN)**
  - Epigenome-wide DNA methylation signatures in cervical pre-invasive and invasive disease  
**Sarah BOWDEN (UNITED KINGDOM)**
  - Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping  
**Stéfanie DICK (NETHERLANDS)**
  - HPV and DNA methylation testing in urine for CIN2/3 and cervical cancer detection  
**Rianne VAN DEN HELDER (NETHERLANDS)**
  - PAX1 and ZNF582 methylation analysis and improvement of cervical cancer screening  
**Bea WISMAN (NETHERLANDS)**
-

**Tuesday, Jun 1 2021****CHANNEL 1****09:00 - 10:30 MSS05 - Methylation Markers****Co-chairs Bea WISMAN (NETHERLANDS), Renske STEENBERGEN (NETHERLANDS)**

Altered DNA methylation is one of the key epigenetic events that contributes to the development of cancer. Methylation of CpG rich regions within promoter regions can lead to gene silencing. HPV-driven carcinogenesis is associated with increased DNA methylation of both host cell tumor suppressor genes as well as viral genes. Change in DNA methylation patterns are already detectable at the stage of precancerous lesions and can be measured in exfoliated cells using sensitive molecular methods. Accordingly, DNA methylation analysis has been evolved as one of the most promising tools for the early detection of cancer and large clinical studies have demonstrated their applicability as triage markers in HPV-based cervical screening. This session will discuss the use of methylation markers for detection of HPV-induced cancers, including both anogenital and oropharyngeal cancers.

- Live introduction  
**Renske STEENBERGEN (NETHERLANDS)**  
**Bea WISMAN (NETHERLANDS)**
  - Methylation markers for detection of cervical (pre)cancer  
**Hung-Cheng LAI (TAIWAN)**
  - Methylation markers for detection of vulvar (pre)cancer  
**Maaïke BLEEKER (NETHERLANDS)**
  - Methylation markers for detection of cervical (pre)cancer in women living with HIV  
**Helen KELLY (UNITED KINGDOM)**
  - Methylation markers for detection of oropharyngeal cancer  
**Elena-Sophie PRIGGE (GERMANY)**
  - Methylation markers for detection of anal (pre)cancer  
**Ramon VAN DER ZEE (NETHERLANDS)**
  - Live discussion  
**Maaïke BLEEKER (NETHERLANDS)**  
**Helen KELLY (UNITED KINGDOM)**  
**Hung-Cheng LAI (TAIWAN)**  
**Elena-Sophie PRIGGE (GERMANY)**  
**Renske STEENBERGEN (NETHERLANDS)**  
**Ramon VAN DER ZEE (NETHERLANDS)**  
**Bea WISMAN (NETHERLANDS)**
- 

**10:45 - 12:15 SS05 - VALIDATION of HUMAN papillomavirus assays and collection DEVICES for HPV testing on Self-samples and urine samples (VALHUDES)****Co-chairs Marc ARBYN (BELGIUM), Steven WEYERS (BELGIUM), Alex VORSTERS (BELGIUM)**

VALHUDES is a framework for comparison and validation of HPV tests applied on vaginal self-samples or on urine. A first VALUDES study is set up in Belgium, where 500 women referred to colposcopy contributed a first-void urine sample, a vaginal self-sample and a cervical specimen taken by a gynaecologist just before colposcopy. Relative sensitivity and specificity estimates for the outcome of CIN2/3+ of HPV testing on urine vs cervical samples and/or HPV testing on vaginal self-samples vs cervical samples are available for the Abbott RealTime High Risk HPV, Anyplex II HPV HR Detection, BD Onclarity HPV Assay, Cobas 4800 HPV Test, RIATOL qPCR and Xpert HPV and will be presented at the EUROGIN Conference.

- Introduction: objectives of VALHUDES  
**Alex VORSTERS (BELGIUM)**
  - Performance of partial genotyping assays on vaginal self-samples vs cervical samples: Abbott RealTime High Risk HPV assay and BD Onclarity HPV assay  
**Ardashel LATSUZBAIA (LUXEMBOURG)**
  - Performance of partial genotyping assays on vaginal self-samples vs on cervical samples: Seegene - Anyplex II HPV HR detection  
**Davy VANDEN BROECK (BELGIUM)**
  - Performance of HPV tests (Abbott RT PCR, BD Onclarity) on first-void urine  
**Severien VAN KEER (BELGIUM)**
  - Attitudes and willingness to use home-based selftests for HPV injection in women invited for Colposcopy (VALHUDES study)  
**Gilbert DONDEERS (BELGIUM)**
  - Principles of validation, summary of VALHUDES findings  
**Marc ARBYN (BELGIUM)**
  - Live discussion  
**Marc ARBYN (BELGIUM)**  
**Gilbert DONDEERS (BELGIUM)**  
**Ardashel LATSUZBAIA (LUXEMBOURG)**  
**Severien VAN KEER (BELGIUM)**  
**Davy VANDEN BROECK (BELGIUM)**  
**Alex VORSTERS (BELGIUM)**  
**Steven WEYERS (BELGIUM)**
-

**12:30 - 13:45 MSS06 - Self-Sampling**

**Co-chairs Danielle HEIDEMAN (NETHERLANDS), Julia BROTHERTON (AUSTRALIA)**

Self-collection of (cervico-) vaginal and urine samples is getting increased attention, particularly to increase screening participation. HPV self-sampling is nowadays offered routinely in the national cervical cancer screening program in certain countries, and other countries have started trials to evaluate the approach as an alternative for clinician-based screening.

- Live introduction  
**Julia BROTHERTON (AUSTRALIA)**  
**Danielle HEIDEMAN (NETHERLANDS)**
- Results of nationwide implementation of HPV self-sampling  
**Sandra VAN DIJK (NETHERLANDS)**
- Self-sampling for older women: the Swedish experience  
**Annika LINDSTRÖM (SWEDEN)**
- Urine self-sampling  
**Alex VORSTERS (BELGIUM)**
- Expectations on primary self-sampling in cervical screening  
**Johannes BERKHOF (NETHERLANDS)**
- Vaginal and urine HPV self-sampling: accuracy and validation guidelines  
**Marc ARBYN (BELGIUM)**
- Live discussion  
**Marc ARBYN (BELGIUM)**  
**Johannes BERKHOF (NETHERLANDS)**  
**Julia BROTHERTON (AUSTRALIA)**  
**Danielle HEIDEMAN (NETHERLANDS)**  
**Annika LINDSTRÖM (SWEDEN)**

**14:00 - 15:30 FC11 - HPV Vaccines II**

**Chair Elmar JOURA (AUSTRIA)**

- HPV vaccination after conization – A systematic review and Meta-Analysis  
**Peter HILLEMANN (GERMANY)**
- Advocating for HPV disease elimination in Europe  
**Peter BAKER (BELGIUM)**
- Effectiveness of HPV vaccination against cervical neoplasia among birth cohorts ineligible for routine vaccination: a population-based study  
**Dong LI (NORWAY)**
- Incidence of new-onset autoimmune conditions among males receiving GARDASIL®  
**Morgan MARKS (USA)**
- Vaccine effectiveness following routine immunization with bivalent HPV vaccine: Protection against genital HPV infections following two doses is comparable to three doses  
**Joske HOES (NETHERLANDS)**
- Inflammation-related adverse reactions following HPV vaccination indicate a stronger immune response  
**Chunlian ZHUANG (CHINA)**
- Monitoring the impact of HPV vaccination on cervical cancer in England: results from 2013-2017 diagnoses in females under 30 years of age  
**Hannah MILBOURN (UNITED KINGDOM)**
- HPV National immunization programmes status in 53 WHO countries  
**Elmar JOURA (AUSTRIA)**
- Human papillomavirus vaccine effectiveness by number of doses: updated systematic review of data from national immunization programs  
**Lauri MARKOWITZ (USA)**
- Frequency of safety events occurring on the day of vaccination with 4-valent human papillomavirus among males  
**Kandace AMEND (USA)**
- HPV vaccination effectiveness within the Ancona cervical screening programme: cohort study  
**Cecilia ACUTI MARTELLUCCI (ITALY)**

**15:45 - 17:45 SS06 - Immunology - Resistance Mechanisms to Immunotherapy**

**Chair Sjoerd H. VAN DER BURG (NETHERLANDS)**

Immunotherapy has secured its place in the realm of standard therapies to treat cancer. Immunotherapy is also establishing itself in HPV-induced cancers albeit with limited success so far. A better understanding of what causes resistance to immunotherapy is key to the design of new immunotherapeutic strategies aiming to improve the clinical outcome. The presentations in this session will highlight some key elements of resistance and provide clues how to work around them.

- Live introduction  
**Sjoerd H. VAN DER BURG (NETHERLANDS)**
- DNA-based immunotherapy for treatment of HPV-16 and/or 18 (HPV16/18) associated vulvar HSIL: phase 2 open label trial efficacy and safety results  
**Amanda M PETRELLIS (USA)**
- An organotypic in vitro model of HPV-associated precancer facilitating preclinical drug testing  
**Richard KOEHLER (GERMANY)**

- Resistant mechanisms in mice: On the influence of suppressive myeloid cells  
**Viktor UMANSKY (GERMANY)**
- Resistant mechanisms in mice: On the acquired immune escape to therapeutic vaccination  
**Sjoerd H. VAN DER BURG (NETHERLANDS)**
- On the primary resistance to therapeutic vaccination or imiquimod therapy in hVIN  
**Ziena ABDULRAHMAN (NETHERLANDS)**
- Resistant mechanisms in patients: Effect of immunosuppressive immune cells for therapeutic vaccination  
**Marij WELTERS (NETHERLANDS)**
- Resistant mechanisms in patients: Escape by antigen presentation alteration  
**Barbara SELIGER (GERMANY)**
- Live discussion  
**Ziena ABDULRAHMAN (NETHERLANDS)**  
**Richard KOEHLER (GERMANY)**  
**Amanda M PETRELLIS (USA)**  
**Barbara SELIGER (GERMANY)**  
**Viktor UMANSKY (GERMANY)**  
**Sjoerd H. VAN DER BURG (NETHERLANDS)**  
**Marij WELTERS (NETHERLANDS)**

**Tuesday, Jun 1 2021**

**CHANNEL 2**

**09:00 - 10:15 FC09 - Economics and Modelling**

**Chair Mark JIT (UNITED KINGDOM)**

- The public health and cost effectiveness impact of 9vhpv vaccination on anal and penile cancers among the HIV-positive and HIV-negative MSM population in Germany – preliminary results from a dynamic transmission model  
**Cody PALMER (USA)**
- Costs of human papillomavirus vaccination in Tanzania: one-dose and two-dose estimates based on national program costs  
**Verena STRUCKMANN (GERMANY)**
- Expediting cervical cancer elimination in the Netherlands while balancing the harms and benefits of cervical cancer screening  
**Erik JANSEN (NETHERLANDS)**
- Optimal screening strategies for unvaccinated women, women offered quadrivalent HPV vaccination and women offered nonavalent HPV vaccination in the US: a CISNET comparative modeling analysis  
**Emi NASLAZI (NETHERLANDS)**

**10:30 - 11:20 FC10 - Anal HPV Infection**

**Chair Laurent ABRAMOWITZ (FRANCE)**

- Incidence and risk factors of anal squamous cell carcinoma in cohort study of patients with severe anal intraepithelial neoplasia AIN<sub>3</sub>  
**Laurent ABRAMOWITZ (FRANCE)**
- Implications of HPV status on clinical outcomes in anal cancer patients in Scotland  
**Daniel GUERENDIAIN (UNITED KINGDOM)**
- Individual patient data meta-analysis on the prognostic significance of P16INK4A and high-risk HPV-TYPE DNA in anal squamous cell carcinomas  
**Theresa OBERMUELLER (GERMANY)**
- A systematic review and meta-analysis of cytology and biomarkers for anal cancer screening  
**Nicolas WENTZENEN (USA)**

**12:00 - 12:30 WF - Workshop Francophone - Part 1 - Histoires naturelles comparées des infections à SRAS-CoV2 et HPV**

**Chair Joseph MONSONEGO (FRANCE)**

- HPV  
**Joseph MONSONEGO (FRANCE)**
- SRAS-CoV2  
**Sophie ALAIN (FRANCE)**

**12:30 - 13:10 WF - Workshop Francophone - Part 2 - Virus, infection et maladies induites : ce qui est commun et ce qui est différent**

Thèmes abordés : Impact populationnel Effets temporels du dépistage et de la vaccination Variants - Mutations Immunité naturelle - Immunité de groupe - Immunité vaccinale

- Virus, infection et maladies induites: ce qui est commun et ce qui est différent  
**Robert COHEN (FRANCE)**  
**Josette RAYMOND (FRANCE)**
- Discussion  
**Emmanuel GRIMPREL (FRANCE)**  
**Isabelle HAU (FRANCE)**  
**Christine KATLAMA (FRANCE)**

---

**13:10 - 13:50      WF - Workshop Francophone - Part 3 - Immunisation : particularités et perspectives**

Thèmes abordés : Technologie (ADN, ARN, adénovirus, adjuvants) Efficacité, tolérance Durée de protection - Mémoire immunitaire  
Nombre de doses - Rappels Vaccination de masse VS Populations à risque VS Individuelle

- Immunisation: particularités et perspectives  
**Benoit SOUBEYRAND (FRANCE)**
  - Discussion  
**Marie-Aliette DOMMARGUES (FRANCE)**  
**Odile LAUNAY (FRANCE)**  
**Didier PINQUIER (FRANCE)**
- 

**13:50 - 14:30      WF - Workshop Francophone - Part 4 - Aspects éthiques et sociétaux : un contexte différent, une problématique commune?**

Thèmes abordés : Défi face à la vaccination Conséquences attendues de la pandémie sur l'hésitation vaccinale La France dans le monde, impact de la communication, évolution des mentalités, les paramètres d'influence et d'acceptabilité Rôle des professionnels de santé, des politiques, des médias et de la société civile Le pass sanitaire

- Aspects éthiques et sociétaux: un contexte différent, une problématique commune?  
**Jeremy WARD (FRANCE)**
  - Discussion  
**Josette RAYMOND (FRANCE)**  
**Jocelyn RAUDE (FRANCE)**  
**François VIÉ LE SAGE (FRANCE)**
- 

**15:00 - 16:20      FC12 - Management II**

- Adherence to follow-up after non-negative HPV-tests among women aged 60-64 and the associated resource use: a register-based cohort study  
**Susanne Fogh JOERGENSEN (DENMARK)**
  - Clinical management of older postmenopausal women referred for colposcopy due to an abnormal screening test  
**Berit Bargum BOUTH (DENMARK)**
  - Colposcopy impression has a key role in the estimation of the risk of HSIL/CIN3  
**Cristina MARTÍ (SPAIN)**
  - Assisted Digital Cervicoscopy (ADC): The modern gynecologic examination  
**Roland DJAOUI (ISRAEL)**
  - Cervical conization between 2013 and 2018 in women 18 to 45 years old – results from a German statutory health insurance claims data analysis  
**Miriam REUSCHENBACH (GERMANY)**
  - A phase 3 multicenter, double blind, prospective, randomized, placebo controlled study to evaluate efficacy and safety of CEVIRA® in patients with cervical high-grade squamous intraepithelial lesions (HSIL)  
**Peter HILLEMANN (GERMANY)**
  - Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel in high-risk HPV infected patients: results of different studies  
**Yann GASLAIN (SPAIN)**
- 

**Tuesday, Jun 1 2021****CHANNEL 3****08:45 - 11:00      WS03 - Colposcopy Course - Part I****Chair                  Jacob BORNSTEIN (ISRAEL)**

Welcome to the EUROGIN Colposcopy course. Taking care of cervical precancer has evolved significantly in recent years. However, the basis remains – Colposcopy. Performing colposcopy necessitates knowledge and experience. In this course you will learn the fundamentals of the use of the colposcope and essentials of diagnosing and treating precancerous cervical lesions. The EUROGIN course has traditionally been led by Professor Albert Singer, and we have the great pleasure of having him with us again this year, co-sharing the leadership of this course with Professor Jacob Bornstein, who headed the IFPC Nomenclature committee that produced the contemporary colposcopy terminology. Synopsis: Colposcopy is the visual examination of the epithelial cervix using either uni- or binocular vision. Specific abnormalities associated with both squamous and glandular precancer can be identified especially after the application of a 5% acetic acid solution. After this application, the abnormalities become visible as a result to changes in the epithelium and blood vessels in the stroma. These changes occur within an area of the cervix called the transformation zone, an area bounded by the junction of vaginal epithelium and the glandular epithelium arising from the endocervix (canal). Within this area a change occurs in which glandular epithelium changes to squamous by a process of transformation, called metaplasia. The upper border of this metaplastic change is called the new squamo-columnar junction. The inability to see this junction means that abnormality may exist higher up in the endo cervix. A sample of any abnormality within the transformation zone can be taken by a simple punch biopsy. Colposcopy is an essential part of the diagnosis and treatment of cervical precancer. It is indicated in the presence of abnormal cytology or in the finding of certain types of HPV and also when there are clinical symptoms and signs of the early invasive cancer. Educational Objectives: Upon completion of this educational activity, participants should be able to: • Describe the anatomy, cytology, histology, and colposcopic findings of the normal and abnormal cervix. • Define the pathophysiology of lower genital tract neoplasia, including the role of HPV in preinvasive and invasive diseases of the cervix. • Define the IFPC colposcopy terminology. • Recognize the diagnostic characteristics of cervical abnormalities (minor-grade and major-grade cervical lesions as well as glandular lesions and cervical cancer) on cytologic, colposcopic, and histologic exam; • Interpret and correlate cytologic, colposcopic, and histologic results. • Describe treatment options to include cryosurgery and large loop excision of the transformation zone (LLETZ) of the cervix. • Provide appropriate patient education and support.



- Opening  
**Jacob BORNSTEIN (ISRAEL)**
  - The normal cervix and the colposcopy examination  
**Albert SINGER (UNITED KINGDOM)**
  - Update in pathology and cytology for colposcopists  
**Christine BERGERON (FRANCE)**
  - Colposcopy of "abnormal" cervix, colposcopic terminology  
**Jacob BORNSTEIN (ISRAEL)**
- 

**11:15 - 13:00      WS03 - Colposcopy Course - Part II**

**Chair                  Jacob BORNSTEIN (ISRAEL)**

- Management protocols of abnormal screening findings - the value of biomarkers  
**Jesper BONDE (DENMARK)**
  - Treatment of cervical precancer  
**Jacob BORNSTEIN (ISRAEL)**
  - Complications of treatment of squamous and glandular cervical precancer  
**Albert SINGER (UNITED KINGDOM)**
  - Interactive session (what is your diagnosis) and Summary of course  
**Albert SINGER (UNITED KINGDOM)**
- 

**13:30 - 14:40      FC13 - HPV Testing / Molecular Markers II**

**Chair                  Bart HESSELINK (NETHERLANDS)**

- Development of HPV testing in men in a routine diagnostic laboratory  
**Angelika STARY (AUSTRIA)**
  - Alternative chemistries for Test Of Cure (TOC) - a retrospective case-control study  
**Hana ELASIFER (UNITED KINGDOM)**
  - Collection and stabilization of urine samples with the COLLI-PEE® device and reagent to facilitate urinary microbiome studies  
**Kyle MACDONALD (CANADA)**
  - Evaluation of the fully automated NeuMoDx HPV assay for cervical cancer screening  
**Bart HESSELINK (NETHERLANDS)**
  - Performance of HPV E6/E7 mRNA assay as primary screening test. Results from the NTCC2 trial  
**Paolo GIORGI ROSSI (ITALY)**
  - Extended genotyping in a HPV positive primary screening population, using the BD Onclarity HPV assay  
**Padmaja NAIK (IRELAND)**
- 

**15:30 - 16:40      FC14 - Public Health**

**Chair                  Marc STEBEN (CANADA)**

- Introduction  
**Marc STEBEN (CANADA)**
  - HPV vaccination beyond school based programs  
**Marc STEBEN (CANADA)**
  - Decision making process of intent to receive Covid-19 vaccination relates to HPV vaccination receipt among young adults in Mountain West region of the United States  
**Deanna KEPKA (USA)**
  - Perceptions on reasons for Pap and HPV testing among healthcare providers in Finland  
**Petra MAKKONEN (FINLAND)**
  - Knowledge and awareness about human papillomavirus and vaccination against it among adolescents and parents in Latvia  
**Jana ZODZIKA (LATVIA)**
  - Investigating the decrease in participation in the Dutch cervical cancer screening programme  
**Clare AITKEN (NETHERLANDS)**
-